Neurology

COVID-19 may up ischaemic stroke severity

Roshini Claire Anthony, 4 hours ago

Patients with COVID-19 who experience an ischaemic stroke may have worse outcomes, including greater stroke severity and mortality risk, than those without COVID-19, findings from the Global COVID-19 Stroke Registry showed.

Resveratrol helps improve cognition, ease osteoarthritis pain in postmenopausal women

4 days ago

Regular supplementation with low-dose resveratrol in postmenopausal women helps improve cognitive function, as well as alleviate chronic pain due to age-related osteoarthritis, according to data from the Resveratrol for Healthy Ageing in Women study.

Candesartan may offer neurocognitive protection against mild cognitive impairment

Audrey Abella, 6 days ago

The ARB* candesartan was superior to the ACEi** lisinopril in improving neurocognitive function in older hypertensive adults with mild cognitive impairment (MCI), a study has shown.

Cerebrovascular disease history ups mortality risk in COVID-19 patients

20 Sep 2020

A history of cerebrovascular disease increases the risk of mortality in patients with the novel coronavirus disease (COVID-19) by 2.78-fold when compared to those with other comorbidities or without underlying pathologies, reveal the results of a recent study.

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.

Eptinezumab improves outcomes, lowers medication use in patients with chronic migraine and medication-overuse headache

Roshini Claire Anthony, 21 Aug 2020

In patients diagnosed with chronic migraine and medication-overuse headache (MOH), treatment with eptinezumab led to improved patient-reported outcomes, fewer migraine days, and a reduction in acute medication use, according to subgroup analyses of the PROMISE-2* trial presented at AHS 2020.

Some antihypertensive meds tied to lower dementia risk

Roshini Claire Anthony, 20 Aug 2020

Calcium channel blockers (CCBs) and angiotensin II receptor blockers (ARBs) may be associated with a reduced risk of dementia, according to a systematic review and network meta-analysis conducted by researchers from the Netherlands.

Pimavanserin may cut symptoms of dementia-related psychosis

Audrey Abella, 20 Aug 2020

Use of the antipsychotic drug pimavanserin led to a substantial reduction in psychosis symptoms in individuals with dementia regardless of severity or subtype, according to the results of the HARMONY trial presented at AAIC 2020.

Plasma P-tau217: Potential biomarker for Alzheimer's?

Pearl Toh, 19 Aug 2020

A new blood test for plasma P-tau217* accurately differentiates Alzheimer's disease (AD) from other neurodegenerative diseases — showing promise as a blood-based biomarker for early detection of AD, according to a study presented at the AAIC 2020 Meeting.